<DOC>
	<DOCNO>NCT02285855</DOCNO>
	<brief_summary>The goal clinical research study learn give metformin combination radiation therapy effective radiation therapy alone . In study , participant receive either metformin placebo . A placebo drug . It look like study drug design treat disease illness . It design compare study drug learn study drug real effect .</brief_summary>
	<brief_title>Metformin Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( roll dice ) receive either metformin placebo . This do one know one study group well , , bad group . For every 7 participant enrol study , 6 receive metformin 1 receive placebo . Only study staff know receive study drug placebo . Study Drug/Placebo Administration : You begin take metformin/placebo 3 week begin radiation therapy . You take week radiation therapy . You take drug/placebo 3 time day ( morning , noon , even ) . To decrease GI side effect start metformin 1000 mg daily divide dose ( morning evening ) 1 week . You keep log time take metformin/placebo . You bring log study visit . You also receive Benadryl ( diphenhydramine ) prednisone help prevent side effect . There change radiation therapy . You receive separate consent form describe radiation therapy risk . Study Visits : Every week take study drug/placebo , blood ( 2-3 teaspoon ) draw routine test . You positron emission tomography-computed tomography ( PET-CT ) scan start metformin/placebo check status disease . Length Study : You may continue take study drug/placebo total 2 week radiation treatment . You longer able take study drug/placebo disease get bad , intolerable side effect occur , unable follow study direction . Follow-Up : Your medical record check 6 month radiation therapy . This investigational study . Metformin FDA approve treatment diabetes . Its use study give radiation therapy treat lung cancer investigational . The study doctor explain study drug design work . Up 70 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients pathologic diagnosis lung NSCLC squamous cell carcinoma . 2 . Patients treat hypofractionated RT . 3 . Patient surgical candidate due medical comorbidities determine thoracic surgeon patient refusal 4 . Patient plan receive treatment MD Anderson 5 . Patients must sign informed consent 6 . Patient must adequate renal function within 30 day prior registration , define serum creatinine within normal institutional limit creatinine clearance least 60 ml/min 1 . Patient : random glucose &gt; 200 mg/dl take oral hypoglycemic agent insulin time study entry 2 . Patient history lactic acidosis , chronic kidney disease creatinine &gt; /= 1.2 mg/dl 3 . Women pregnant breast feeding , treatment involve unforeseeable risk participant , embryo , fetus , nurse infant 4 . Patients history allergic reaction metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Stereotactic body radiotherapy</keyword>
	<keyword>SBRT</keyword>
	<keyword>XRT</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>Metformin</keyword>
	<keyword>Metformin ER</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sugar pill</keyword>
	<keyword>Lung adenocarcinoma</keyword>
	<keyword>Genotypes</keyword>
	<keyword>Genetic mutation</keyword>
</DOC>